The potential Pfizer bid for AZ (both BIA members) dominates at Westminster this week with both the Business and Science Select Committees hearing from senior leadership of both companies as well as government ministers and the unions on Tuesday and Wednesday. Whilst I do not intend to provide a running commentary on the process it’s clear to me that the views of many MPs and civil servants of the sector are being forged through thinking about the implications of any deal, and, whatever the outcome, the framing of the policy landscape for our sector will be different by the summer.
Although you wouldn’t find so much of it in the media, other companies have made progress in the last week or two as SkyePharma raised £112 million, Oxford BioMedica were awarded a £2.2 million grant from Biomedical Catalyst to help fund Phase I/II clinical trial of OXB-102 in Parkinson’s disease patients, and Shire acquired Fibrotech for US$75 million.
In the week when the Royal Pharmaceutical Society published their report on antimicrobial resistance, calling for new funding for research into that area, it was great to see member Euprotec announce its collaboration with Cantab Anti-infectives to identify and develop novel antibiotics following its £2.3m funding award from the Biomedical Catalyst.
Our blog is worth a read this week with great pieces from GSK on their recent deal with Novartis and from UCB highlighting new ways for academics and SMEs to partner with them on monoclonal antibody discovery.
Fancy your company as the Most Innovative EU SME Biotech? Unlike Eurovision the UK (and BIA members) have a succesful recent record in this competition; the current holders are PsiOxus Therapeutics. It’s straightforward to apply and applications are being accepted right now.
I wish those of you at BioTrinity a very successful meeting, and if you’d like to discuss these latest moves further then there is no better place than our Science and Finance in the City networking reception this Thursday – click here as it’s your last chance to book. I look forward to seeing you there to hear the latest from Kit Malthouse to catch up in great surroundings.